ATS 2019 Virtual Final Program

918 Nocturnal Hypoxemia Measured by Polysomnogram Is Associated with Acute Chest Syndrome in a Pediatric Sickle Cell Disease Population/ P.A. Nourani, M.H. Maddox, J. Lebensburger, B. Pernell, A.S. Alishlash, Birmingham, AL, p.A4388 919 Retrospective Cohort Study of Asthma Management in Pediatric Patients with Sickle Cell Disease/ S. Saxena, J. Pappas, E. Bracey, K. Smith-Whitley, O. Afolabi-Brown, J. Allen, A. Bhandari, Philadelphia, PA, p.A4389 920 Recessive DNAH9 Loss-of-Function Mutations Cause Absence of ODAs Type 2 and Only Subtle Respiratory Ciliary Beating Defects/ H. Omran, I.M. Hoeben, T. Noethe-Menchen, L. Jelten, D. Frank, C. Werner, J. Tebbe, R. Hjeij, B. Dwornicziak, P. Pennekamp, H. Olbrich, N.T. Loges, Muenster, Germany, p.A7385 921 Abnormal Pulmonary Lymphatic Flow in Patients with Lymphatic Anomalies and Respiratory Compromise on MR Lymphangiogram/ M. Itkin, D. Rabinowitz, G. Nadolski, P. Stafler, L. Mascarenhas, D. Adams, Philadelphia, PA, p.A7386 BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION C26 LET IT BLEED: ENDOTHELIAL INJURY AND ANGIOGENESIS IN PULMONARY HYPERTENSION 9:15 a.m. - 11:15 a.m. KBHCCD Room C141/C143/C149 (Level 1) Poster Viewing 9:15-10:00 Discussion 10:00-11:15 Chairing: A.J. Bryant, MD, Nashville, TN M. Rabinovitch, MD, Stanford, CA A. Smith, MD, Philadelphia, PA 201 Does Veno-Venous Extracoporeal Membrane Oxygenation Reduce Pulmonary Arterial Pressure at Alveolar Hypoxia? A Porcine Experimental Study/ B. Holzgraefe, H. Kalzén, A.S. Larsson, Uppsala, Sweden, p.A4390 202 Impairment of Endothelial Caveolin-1-TRPV4 Channel Signaling in Pulmonary Hypertension/ C. Marziano, K. Hong, E.L. Cope, M. Ottolini, S.K. Sonkusare, Charlottesville, VA, p.A4391 203 Targeting ADORA1/PDE10A Signalosome Regulated cAMP Microenvironment as a Novel Therapeutic Approach for Treating Pulmonary Hypertension/ C. Valasarajan, J.C.P. Laria, N.C.P. Laria, A. Wietelmann, F. Grimminger, W. Seeger, S.S. Pullamsetti, Bad Nauheim, Germany, p.A4392 204 Locus 7q36.1 Harbors a Flow-Sensitive Endothelial Enhancer/ H.T. Duong, D.L. Harrison, M.D. Krause, R.-T. Huang, Y. Fang, Chicago, IL, p.A4393 205 Car, A Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil/ A. Keshavarz, A. Alobaida, T. Al-Hilal, F. Ahsan, Amarillo, TX, p.A4394 206 ACTRIIA-Fc (Sotatercept) Reverses Pulmonary Vascular Remodeling to Attenuate Pulmonary Arterial Hypertension (PAH) by Rebalancing TGF-b/BMP Signaling in a Preclinical Model/ S.R. Joshi, J. Liu, R.S. Pearsall, G. Li, R. Kumar, Cambridge, MA, p.A4395 207 Circulating Serum ST2 as a Biomarker of Disease Severity and Survival in Pulmonary Arterial Hypertension/ C. Simpson, R.L. Damico, P.M. Hassoun, J. Yang, M. Nies, M. Griffiths, D. Vaidya, S. Brandal, M. Pauciulo, E.D. Austin, D. Ivy, W.C. Nichols, A. Everett, Baltimore, MD, p.A4396 208 Sorting Nexin 29 (SNX29) as a Novel Biomarker for Vasoresponsive Pulmonary Arterial Hypertension/ J. Karnes, T. Thayer, A. Arora, K. Batai, S. Halladay, K. Lutz, A. Coleman, M. Pauciulo, R. Kittles, J.G.N. Garcia, J.X.J. Yuan, M.W. Geraci, J.D. West, A. Hemnes, R. Stearman, W.C. Nichols, E. Brittain, A.A. Desai, Tucson, AZ, p.A4397 209 Endothelial-Specific Knockdown of Lung WWOX Expression Worsens Acute Lung Injury/ S. Singla, Z. Zeng, W. Chen, R. Demeritte, J. Chen, J.R. Jacobson, S.M. Dudek, V. Natarajan, R.F. Machado, Chicago, IL, p.A4398 210 Anti-IL-6 Treatment Ameliorates the Pulmonary Hypertension Phenotype in Tnfaip3DNGR1-KOMice/ T. Koudstaal, J.A. van Hulst, P. Heukels, D. Merkus, M.A. de Raaf, I.M. Bergen, H.J. Bogaard, L. Boon, G. van Loo, J.G. Aerts, R.W. Hendriks, K.A. Boomars, M. Kool, Rotterdam, Netherlands, p.A4399 211 NEDD9 Is a Modifiable Target of Platelet-Pulmonary Artery Endothelial Cell Adhesion/ G.A. Alba, Y.-Y. Zhang, A. Samokhin, B. Wertheim, E. Arons, S. Seo, R.N. Channick, E. Battinelli, B. Maron, Boston, MA, p.A4400 212 Cyclic Car Peptide Targets Pulmonary Vascular Endothelium and Enhances the Efficacy of Prostacyclin in Experimental Pulmonary Hypertension/ L.-M. Yung, P. Yang, T. Dinter, G. Bocobo, Z. Augur, A.B. Waxman, D. Man, P.B. Yu, Boston, MA, p.A4401 213 Real-Time Characterization of Inflammatory Lung Injury/ P.G. Belvitch, H. Wang, W. Chen, L. Meliton, J.G.N. Garcia, J.R. Jacobson, S.M. Dudek, Chicago, IL, p.A4402 214 Serum Chloride Is a Prognostic Marker in Pulmonary Arterial Hypertension/ K. Prins, E. Brittain, T.R. Assad, R. Kalra, L. Rose, S.L. Archer, E.K. Weir, M. Pritzker, T. Thenappan, Minneapolis, MN, p.A4403 215 Angiogenic Profile Identifies Pulmonary Hypertension in Children with Down Syndrome/ D.S. Bush, D. McMorrow, K. Wolter-Warmerdam, B.D. Wagner, C. Galambos, D. Ivy, S.H. Abman, F. Hickey, New York, NY, p.A4404 216 HIV-Nef Protein Persists in Bronchoalveolar Lavage Derived Extracellular Vesicles of HIV Patients on ART and Induces EMAPII Amplified Endothelial Cell Apoptosis Resulting in Pulmonary Vascular Pathologies Like Pulmonary Hypertension/ S. Chelvanambi, N.V. Bogatcheva, P. Jolicoeur, H.L. Twigg, M. Clauss, Indianapolis, IN, p.A4405 ATS 2019 • Dallas, TX TUESDAY • MAY 21 235 TUESDAY MORNING